Therapeutic compounds
US-2018319751-A1 · Nov 8, 2018 · US
Substituted phenothiazines as mitochondrial agents
US10472340B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10472340-B2 |
| Application number | US-201615550282-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 17, 2016 |
| Priority date | Feb 17, 2015 |
| Publication date | Nov 12, 2019 |
| Grant date | Nov 12, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides phenothiazine derivative compounds and salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of diseases associated with decreased mitochondrial function resulting in diminished ATP production and/or oxidative stress and/or lipid peroxidation.
First claim
Opening claim text (preview).
We claim: 1. A compound selected from the group consisting of: 2. The compound of claim 1 , wherein the compound is selected from the group consisting of: 3. The compound of claim 1 , wherein the compound is selected from the group consisting of: 4. The compound of claim 1 , wherein the compound is selected from the group consisting of: 5. The compound of claim 1 , wherein the compound is selected from the group consisting of: 6. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, excipient and/or diluent. 7. A compound: 8. A pharmaceutical composition comprising the compound according to claim 7 and a pharmaceutically acceptable carrier, excipient and/or diluent.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the cardiovascular system · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Anti-Parkinson drugs · CPC title
for treating abnormal movements, e.g. chorea, dyskinesia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10472340B2 cover?
- The present disclosure provides phenothiazine derivative compounds and salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of diseases associated with decreased mitochondrial function resulting in diminished ATP production and/or oxidative stress and/or lipid peroxidation.
- Who is the assignee on this patent?
- Univ Arizona State
- What technology area does this patent fall under?
- Primary CPC classification C07D279/20. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).